Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.

Objective: To evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non-small cell lung cancer (NSCLC) and assess their potential impact on the care of patients.

Data Sources: A comprehensive literature search of PubMed and Clinicaltrials.gov was conducted using the terms , , , , ,

Study Selection And Data Extraction: Relevant English-language clinical trials were evaluated.